Pancreatic cancer surgery may benefit from MasSpec Pen innovation
In a groundbreaking development, the MasSpec Pen technology is set to revolutionise the field of precision medicine, as it can now be utilised in real-time during surgical procedures. This breakthrough was highlighted in a recent study published in the prestigious journal, Proceedings of the National Academy of Sciences, with the DOI for the article being 10.1073/pnas.210441118.
Led by Livia Schiavinato Eberlin, a university investigator, this research has been meticulously conducted with transparency and disclosure of all potential conflicts of interest, a commitment upheld by the University of Texas at Austin. Dr. Eberlin is a co-founder and holds an equity stake in MSP Technologies, an inventor-led startup formed to commercialise the MasSpec Pen technology, owned by the university.
The MasSpec Pen, a diagnostic tool, has been tested for the first time in pancreatic cancer patients during surgery. It demonstrates an extraordinary ability to accurately identify margins between healthy and cancerous tissue, which can significantly enhance the chances of survival for patients undergoing pancreatic cancer surgeries.
The technology's speed is another notable advantage, as it is more than 100 times as fast as the current gold standard diagnostic, Frozen Section Analysis. This speed allows for immediate, accurate results, potentially streamlining the surgical process and improving patient outcomes.
The MasSpec Pen has shown promising results in preclinical research published in 2017, leading to widespread enthusiasm and interest. The tool has been tested in more than 150 human surgeries, including for breast and thyroid, further validating its potential.
The study's results were supported in part by the National Cancer Institute of the National Institutes of Health, and by the Gordon and Betty Moore Foundation. Banked tissue samples were provided by the Cooperative Human Tissue Network and Baylor.
The research group that tested the MasSpec-Pen diagnostic device is affiliated with the University Hospital Jena (Universitätsklinikum Jena). Notably, Dr. Eberlin has submitted required financial disclosure forms with the university, ensuring the utmost transparency in this groundbreaking research.
In summary, the MasSpec Pen represents a significant leap forward in the realm of precision medicine. Its ability to accurately identify tissues and surgical margins directly in patients during surgery has the potential to transform the way we approach surgeries, particularly for cancer patients. The future of surgical diagnostics looks promising with this innovative technology.
Read also:
- Understanding Hemorrhagic Gastroenteritis: Key Facts
- Stopping Osteoporosis Treatment: Timeline Considerations
- Tobacco industry's suggested changes on a legislative modification are disregarded by health journalists
- Expanded Community Health Involvement by CK Birla Hospitals, Jaipur, Maintained Through Consistent Outreach Programs Across Rajasthan
